MVT 602

Drug Profile

MVT 602

Alternative Names: MVT-602; RVT-602; TAK-448

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium
  • Developer Millennium; Myovant Sciences; Takeda; Takeda Oncology
  • Class Infertility therapies; Oligopeptides
  • Mechanism of Action Hormone stimulants; KISS1R protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Female infertility; Hypogonadism
  • Discontinued Prostate cancer

Most Recent Events

  • 10 Oct 2018 Safety, efficacy and pharmacokinetics data from a phase I trial in healthy volunteers (In females) released by Myovant Sciences
  • 24 Jun 2018 Biomarkers information updated
  • 23 May 2018 Phase-II clinical trials in Female infertility (In volunteers) in Netherlands (SC) (EudraCT2018-001379-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top